Clinical investigation of medicinal products for the treatment of acute heart failure

  • Email
  • Help
Current effective version

Revision 1 - Adopted guideline

Reference numberCPMP/EWP/2986/03 Rev.1
Published10/06/2015
Effective from01/12/2015
KeywordsAcute heart failure, acute decompensated heart failure, acute heart failure syndromes, chronic heart failure, dyspnoea, B-type natriuretic peptide (BNP)
DescriptionThis document provides guidance on the main regulatory requirements for the development of a medicinal product for the treatment of acute heart failure in adults. It focueses mainly on pharmacological intervention of left ventricular dysfunction with or without concomitant right ventricular dysfunction.


Document history

Revision 1 

Current version

Adopted guideline


Draft guideline


Concept paper

In operation: 01/12/2015–present


Published: 15/10/2012


Published: 04/06/2010

First versionAdopted guidelineIn operation: 01/01/2005–30/11/2015


Related content


How helpful is this page?

Average rating:

 Based on 0 ratings

Add your rating:

See all ratings
0 ratings
0 ratings
0 ratings
0 ratings
0 ratings
    

Tell us more